Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Completes $800M Notes Offering; Buys Back Shares

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Illumina said after the close of the market Friday that it has closed its offering of $800 million principal amount of .25 percent convertible senior notes due 2016.

The San Diego-based firm announced the offering earlier in the week, and said that it also has granted initial purchasers a 30-day option to purchase up to $120 million of additional notes.

Illumina said Friday that it used $314.3 million of the net proceeds from the offering to purchase 4,890,500 shares of its common stock through privately negotiated transactions concurrent with the senior notes offering. In addition, the firm intends to use between $260 million and $390 million to fund conversions of its currently outstanding convertible notes.

Illumina intends to use the balance of the proceeds for general corporate purposes, which could include acquisitions and additional purchases of its common stock.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.